Samsung Medical Center

Seoul, Seoul Teugbyeolsi 135-710

4 studies enrolling now · 15 studies all time

What they study most

Advanced or Metastatic Solid Tumors, Advanced/Metastatic Solid Tumors, Alzheimer Disease, B-cell Lymphoid Malignancies, C. Diff Infection, C.Difficile Diarrhea, CDI, Clostridioides Difficile Infection, Clostridioides Difficile Infection Recurrence, Clostridium Difficile, Clostridium Difficile Infection Recurrence, Clostridium Difficile Infections

Studies at this site

• A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) — Recruiting now
• A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) — Recruiting now
• VE303 for Prevention of Recurrent Clostridioides Difficile Infection — Recruiting now
• ADG126 in Combination With Pembrolizumab in Patients With Advanced/Metastatic Solid Tumors — Recruiting now
• A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma — Running, not enrolling
• A Study of Vedolizumab in Children and Teenagers With Moderate to Severe Ulcerative Colitis (UC) — Completed
• A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With RAS Q61X Mutations — Running, not enrolling
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Diabetic Macular Edema — Running, not enrolling
• Study to Assess the Efficacy & Safety of KHK4951 in Patients With Neovascular Age-Related Macular Degeneration — Running, not enrolling
• Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer — Completed
• A Study of Tislelizumab (BGB-A317) Versus Chemotherapy as Second Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma — Completed
• BGB 3111 in Combination With Obinutuzumab in Participants With B-Cell Lymphoid Malignancies — Completed
• A Study of BBI608 Plus Weekly Paclitaxel to Treat Gastric and Gastro-Esophageal Junction Cancer — Completed
• A Study of Napabucasin (BBI-608) in Combination With FOLFIRI in Adult Patients With Previously Treated Metastatic Colorectal Cancer — Completed
• A Study of PEGylated Recombinant Human Hyaluronidase in Combination With Nab-Paclitaxel Plus Gemcitabine Compared With Placebo Plus Nab-Paclitaxel and Gemcitabine in Participants With Hyaluronan-High Stage IV Previously Untreated Pancreatic Ductal Adenocarcinoma — Stopped early